 VICTORIA, British Columbia ROCKVILLE, Md.--BUSINESS WIRE--Aurinia Pharmaceuticals Inc. NASDAQ: AUPH TSX: AUP Aurinia or the Company today announced that The Lancet, an international, peer-reviewed medical journal, published the results of the Companys Phase 3 AURORA 1 study evaluating LUPKYNIS voclosporin in adults with lupus nephritis LN. The AURORA 1 study results demonstrate that LUPKYNIS in combination with mycophenolate mofetil MMF and low-dose corticosteroids led to s 